Treatment News : Twice-Daily ARV Treatment Better than Once-Daily for Some

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 16, 2010

Twice-Daily ARV Treatment Better than Once-Daily for Some

Even though people living with HIV may be more likely to adhere to a Kaletra (lopinavir/ritonavir)-based treatment regimen taken once a day compared with twice a day, those with high pre-treatment viral loads may experience virologic failure faster using Kaletra’s once-daily dosing option, according to a study published in the April 1 issue of Clinical Infectious Diseases.

Research—both inside and outside the world of HIV—has confirmed that people are generally better able to take their medication as prescribed (in other words, to maintain better adherence) if they take treatments once per day compared with multiple times per day.

With HIV, however, the consequence of a missed dose on once-daily treatment can be more significant than missing a twice-a-day dose. This is because the time spent with diminishing levels of antiretroviral (ARV) therapy while waiting for the next dose is twice as long with once-daily treatment, and persistently low levels of ARV drugs in the blood is the recipe for developing drug resistance. There have been questions, therefore, about whether twice-daily treatment might actually help people maintain control of HIV better than once-daily treatment, despite an adherence advantage for the latter.

To determine both adherence rates and maintenance of viral suppression among patients using once- or twice-daily regimens containing Kaletra—a protease inhibitor that is approved using either dosing strategy for first-time treatment takers—Charles Flexner, MD, from Johns Hopkins University in Baltimore and his colleagues enrolled 321 people into the AIDS Clinical Trials Group (ACTG) 5073 study. In all, 160 people took Kaletra twice daily, while 161 took Kaletra once daily. People in both arms combined their Kaletra with Emtriva (emtricitabine) plus either Zerit (stavudine) or Viread (tenofovir).

Once-daily treatment trumped twice-daily treatment in terms of adherence. People taking once-daily treatment took their ARV doses properly 91 percent of the time, while people on twice-daily treatment took their doses as prescribed 80 percent of the time. The difference in adherence didn’t translate into better control of the virus, however. Maintenance of a viral load less than 200 copies was almost identical between both groups.

In the analysis of people starting treatment with viral loads in excess of 100,000 copies, those taking twice-daily treatment had an edge. Among those with high viral loads, 89 percent of those on twice-a-day treatment achieved and maintained a viral load of less than 200 copies during 48 weeks, compared with only 76 percent of those on once-a-day treatment.

“This study demonstrates that although [once-daily] administration improves adherence, the risk of [lower blood level concentrations of the drug between doses] may offset the benefit for selected patients,” the authors concluded.

Search: Once-daily, QD, Twice-daily, BID, Kaletra, ritonavir, lopinavir, adherence, Charles Flexner


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    chrisf
    san jose
    California


    zeze42
    Bay Area - Peninsula
    California


    max38man
    Chicago
    Illinois


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.